Predictors of Response to Intravitreal Bevacizumab in Diabetic Macular Edema: A Prospective Study in Tanzania
DOI:
https://doi.org/10.64666/joecsa.2026.89Keywords:
Bevacizumab, intravitreal injection, Diabetic Macular Edema, diabetic retinopathyAbstract
Purpose: To assess the clinical outcomes and predictors of response to intravitreal bevacizumab injections (IVB) in patients with diabetic macular edema (DME) at Muhimbili National Hospital (MNH).
Methodology: A prospective longitudinal study was conducted at MNH for six months. Patients received monthly IVB (1.25 mg/0.05 mL) for three consecutive months. Baseline and post-treatment assessments included ocular examination, spectral-domain optical coherence tomography (OCT), and laboratory investigations. Main outcome measures were changes in best-corrected visual acuity (BCVA, logMAR) and central macular thickness (CMT, µm) at 12 weeks. Data were analyzed using SPSS v25 with paired t-test and linear regression, and p < 0.05 was considered statistically significant.
Results: Of the 60 patients, 58.3% were male, with a median age of 60.5 years (IQR 44). More than half (56.7%) had diabetes for 11–20 years, and 83.3% had HbA1c >7%. Baseline mean BCVA was 0.876 ± 0.592 logMAR, and mean CMT was 453.02 ± 71.94 µm. At 12 weeks, mean BCVA improved by 0.216 ± 0.523 logMAR (p = 0.002), equivalent to a >10-letter gain, and mean CMT decreased by 95.78 ± 57.65 µm (p < 0.001). Longer diabetes duration was significantly associated with less CMT reduction, with each additional year corresponding to a 0.434 µm increase in CMT (p = 0.003). Elevated HbA1c also predicted poor anatomical response, with each 1% increase associated with a 0.434 µm increase in CMT (p = 0.003).
Conclusion: Three intravitreal bevacizumab injections (IVB) resulted in a significant reduction in diabetic macular edema, marked by a decrease in central macular thickness and accompanied by a significant improvement in mean best-corrected visual acuity. Longer diabetes duration and poor glycemic control predict poor anatomical response, highlighting the importance of integrated diabetes management and structured treatment protocols in resource-limited settings.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Heavenlight masuki, Zuleikha Haji

This work is licensed under a Creative Commons Attribution 4.0 International License.
JOECSA publishes all content Open Access under the Creative Commons Attribution 4.0 International License (CC BY 4.0). Authors retain copyright. Anyone may share and adapt the work for any purpose, provided appropriate credit is given to the original author(s) and the source. License: https://creativecommons.org/licenses/by/4.0/
